R. Scott Struthers

R. Scott Struthers is the founder and CEO of Crinetics Pharmaceuticals. R. has over 25 years of experience in the pharmaceutical industry, with a focus on endocrinology and metabolism. Prior to founding Crinetics, they were Sr. Director & Head of Endocrinology & Metabolism at Neurocrine Biosciences, where they initiated and led the oral GnRH antagonist program resulting in elagolix, a first in class NCE for women's health. Elagolix (now Orilissa) was approved for the treatment of endometriosis in July of 2018 and is in registration for the treatment of uterine fibroids.

Before joining Neurocrine, Dr. Struthers co-founded Sciencemedia Inc., a company that brought high-end visualization and simulation to science education. R. also served as Manager of Contract Research at Biosym Technologies and as a PhD student at The Salk Institute.

In addition to their work in the pharmaceutical industry, Dr. Struthers is also a co-founder and past president of the San Diego Entrepreneurs Exchange, a networking organization for entrepreneurs in San Diego.

R. Scott Struthers received their PhD in Physiology & Pharmacology from UC San Diego.

Marc Wilson - Chief Financial Officer, Alan S. Krasner - Chief Medical Officer, and Ajay Madan - Chief Development Officer report to R. Scott Struthers.